Last updated on June 2019

A Study of Parsaclisib in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)


Brief description of study

This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in subjects with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor.

Clinical Study Identifier: NCT03235544

Find a site near you

Start Over

St Joseph Heritage Healthcare

Santa Rosa, CA United States
  Connect »

ASCLEPES Research Centers

Brooksville, FL United States
  Connect »

Moffitt Cancer Center

Tampa, FL United States
  Connect »

Hattiesburg Clinic

Hattiesburg, MS United States
  Connect »

Clinical Research Alliance

New Hyde Park, NY United States
  Connect »

Kaiser Permanente Northwest

Portland, OR United States
  Connect »

Gettysburg Cancer Center

Gettysburg, PA United States
  Connect »

USOR - Texas Oncology

Austin, TX United States
  Connect »

USOR - Texas Oncology

San Antonio, TX United States
  Connect »

Renovatio Clinical

The Woodlands, TX United States
  Connect »

USOR - Texas Oncology

Tyler, TX United States
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »

Gustave Roussy

Villejuif, France
  Connect »

Kliniken Maria Hilf

Moenchengladbach, Germany
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »